MRAM — OVERWEIGHT · rohit gudi

Portfolio Decision

Gradually build a 3% portfolio position in MRAM using a two-tranche entry: 1.5% at current levels and 1.5% on a pullback toward $13-14 or after five consecutive days above $16. Place a stop-loss at $12.50. The $40M defense contract and 10-year Microchip foundry partnership represent genuine business transformation, but the current deeply overbought technical setup and 42% single-day spike demand disciplined entry timing. Avoid adding above $19; exit below $12.50.

Everspin Technologies has secured two transformational catalysts that fundamentally reshape its revenue trajectory and competitive moat. The $40M defense contract with a U.S. prime contractor — representing 73% of current TTM revenue — provides rare revenue visibility and validates MRAM as a defense-critical technology with no domestic alternative supplier. The 10-year Microchip foundry partnership solves Everspin's manufacturing concentration risk and provides ITAR-compliant second-source capacity, opening the door to broader defense and aerospace adoption. Revenue could approach $70M+ annually as these contracts ramp, pushing the company into sustained profitability with operating leverage on its 51% gross margin base.

However, the current price of $18.78 substantially anticipates this improvement. The stock is deeply overbought: 79% above the 50 SMA, 99% above the 200 SMA, well above the upper Bollinger Band, with bearish MACD divergence and a VWMA ($12.54) far below the closing price. Even the bull's own optimistic earnings model supports a market cap below the current $438M, and the analyst consensus price target of $14 implies meaningful downside. Insider selling remains a caution signal. Small-cap liquidity risk further warrants careful position sizing.

An Overweight rating with a scaled entry strategy captures the multi-year upside while respecting the near-term pullback probability. The defining metric: whether MRAM holds above $16 for five trading days post-spike — that distinguishes sustainable re-rating from a momentum event.

Research Manager

Investment Plan — Overweight

Rationale:

The $40M defense contract and 10-year Microchip foundry partnership are transformational, addressing revenue concentration and manufacturing capacity risks. However, at $18.78 the stock prices in significant future success: forward P/E 75, 50% above analyst fair value, deeply overbought technicals with bearish MACD divergence, consistent insider selling. An Overweight position acknowledges the positive trajectory while respecting elevated entry risk — gradually building exposure allows participation in the re-rating while managing pullback risk.

Strategic Actions:

Initiate half-position now, add on pullback toward $13-14. Stop-loss at $12.00. Target 3-4% portfolio position over 30 days. Avoid chasing above $19. On sustained move above $20 with 3M+ confirming volume, consider increasing position.

Trader

Transaction Proposal — Buy

Action: Buy

Reasoning: Everspin's fundamentals have inflected positively with the $40M defense contract and 10-year Microchip foundry partnership, justifying a directional buy. However, the current $18.78 is deeply overbought. Execute scaled entry: 50% of position immediately, 50% on pullback toward $13-14.

Entry Price: $14.00 (second tranche target; first at market ~$18.78)

Stop Loss: $12.00

Position Sizing: 3% of portfolio (half now, half on pullback)

FINAL TRANSACTION PROPOSAL: BUY

Investment Debate

Bull Researcher

Bull Round 1: $40M defense contract is transformational (73% of TTM revenue), 10-year Microchip deal solves manufacturing risk and builds moat, technicals confirm with golden cross and institutional volume, $44.5M cash with improving profitability trajectory.

Bull Round 2: Analyst targets predate catalysts and need revision, insider selling is 10b5-1 programmed not bearish, MACD still strongly positive, small-cap inflection stories see 2-3x moves, business worth well above $18.78 in 12-18 months with $70M+ revenue and improving margins.

Bear Researcher

Bear Round 1: 8x revenue multiple for barely profitable company, forward P/E 75, deeply overbought (79% above 50 SMA, 99% above 200 SMA, RSI 80+, bearish MACD divergence), insider selling at lower prices, analyst target $14 vs $18.78 price, 42% spike looks like momentum chase.

Bear Round 2: Bull's own earnings model supports market cap below current level, defense contracts can be restructured/cut, MRAM market is still niche, small-cap liquidity trap with 23M float, consistent insider selling at every price level, 4.2% annual dilution rate.

Risk Assessment

Aggressive

Aggressive Round 1: Buy full 4% position now, risk of missing the move outweighs pullback risk, defense contract is sole-source moat, Microchip fab is copy-exact low technical risk.

Aggressive Round 2: Defense programs don't get cancelled once contracted, copy-exact process has low risk, bull's own model shows $320-400M market cap support, opportunity cost of waiting exceeds downside risk.

Conservative

Conservative Round 1: Valuation disconnect ($438M on $55M revenue), single-event dependency on two contracts, extreme overbought readings guarantee mean-reversion, insider selling pattern, recommend 1.5% max and wait for confirmed hold above $14.

Conservative Round 2: Bull's own earnings model supports market cap BELOW current level, defense contracts do get cut, MRAM market is niche, small-cap liquidity trap makes exiting difficult, do not chase above $16.

Neutral

Neutral Round 1: Both sides valid, trader's scaled approach is reasonable but modify second tranche trigger: add after 5 days holding above $16 OR on pullback to $14. Position sizing at 3% is appropriate.

Neutral Round 2: Conservative's valuation math is compelling — even bull model supports market cap below current. Recommended: 1.5% first tranche, 1.5% second on pullback to $13-14 OR after 5 days above $16, stop at $12.50. If stock drops below $16 within 5 days, do NOT add second tranche.

Analyst Reports

Daily close (warm umber) with under-fill, volume bars in tan. Trailing range capped at 252 trading days.

Market Analysis

MRAM closed at $18.78 on April 30, 2026 — a 42.4% single-day gain on 6.89M shares volume. The stock had already risen 50% from $8.79 (Mar 31) to $13.19 (Apr 29). The 50/200 SMA golden cross confirmed in early April. MACD is strongly positive (+0.945) but histogram shows bearish divergence since Apr 17 peak. RSI likely exceeded 80 after the Apr 30 spike. Price is far above the upper Bollinger Band ($14.72). ATR surging to 0.824. VWMA at $12.54 versus $18.78 close signals weak volume conviction at highs. The stock is deeply overbought across all indicators.

Fundamental Analysis

Everspin Technologies (MRAM) — Market Cap $438M, Forward P/E 75.2, P/B 6.27. Revenue growing sequentially: Q1 2025 $13.14M to Q4 2025 $14.80M (TTM $55.2M). Gross margin 51.2%. Operating margin -7.2% improving. Net income TTM -$586K but Q4 2025 delivered +$1.2M. Cash $44.5M, minimal debt $3.3M, current ratio 4.84. Free cash flow volatile. Key catalysts: $40M defense contract (2.5 years, ~73% of TTM revenue), 10-year Microchip foundry partnership for onshore ITAR-compliant MRAM manufacturing. Insider selling pattern (CEO sold 19,440 shares at $9.20 on Apr 1). Analyst price target trimmed from $15 to $14, fair value $12.50.